During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...

A phase 1 trial evaluating FSHR-targeting CAR T cells for patients with ovarian cancer has dosed the first patient in its ...

Aman Chauhan, MD, highlights an ongoing phase 2 trial exploring the combination of triapine, a radiation sensitizer, with ...

Martin Dreyling, MD, University Hospital LMU Munich, in Germany, discusses the final follow-up results of the TRIANGLE study ...

In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed ...

Panelist discusses how there are many significant attributes of the bispecific antibody, which has broader applicability and ...

On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...

During a Case-Based Roundtable® event, Hira Shaikh, MD, and participants discussed how they would treat a patient with ...

Sanjay K. Juneja, MD, hematologist & medical oncologist at Mary Bird Perkins Cancer Center, discusses how artificial ...

Olaparib Demonstrates Survival Benefit in Early Breast Cancer: Data from the phase 3 OlympiA trial (NCT02032823) showed that ...

Sanjay K. Juneja, MD, discusses how artificial intelligence has evolved in 2024 to help improve early detection of cancer.

In January 2024, the FDA approved erdafitinib (Balversa) for adult patients with locally advanced or metastatic urothelial ...